Contineum Therapeutics (CTNM) Cash from Investing Activities (2023 - 2026)

Contineum Therapeutics' Cash from Investing Activities history runs 4 years deep, the most recent figure standing at -$39.3 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 363.55% year-over-year to -$39.3 million in Q1 2026; TTM through Mar 2026 was -$57.9 million, a 8.84% increase from a year earlier, with the FY2025 full-year figure at -$3.7 million, up 94.68% from the prior year.
• Cash from Investing Activities advanced to -$39.3 million in Q1 2026 per CTNM's latest filing, from -$47.5 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $14.9 million in Q3 2025 and bottomed at -$47.5 million in Q4 2025.
• The 4-year median for Cash from Investing Activities is -$9.4 million (2024), against an average of -$13.7 million.
• Biggest YoY gain for Cash from Investing Activities was 149.5% in 2025; the steepest drop was 405.46% in 2025.
• Year by year, Cash from Investing Activities stood at $9.0 million in 2023, then slumped by 203.96% to -$9.4 million in 2024, then sank by 405.46% to -$47.5 million in 2025, then gained by 17.16% to -$39.3 million in 2026.
• Per Business Quant, the three latest CTNM Cash from Investing Activities figures stand at -$39.3 million (Q1 2026), -$47.5 million (Q4 2025), and $14.9 million (Q3 2025).